NkGen Biotech will present clinical and biomarker data on troculeucel, an autologous ex vivo expanded natural killer cell candidate, at the 4th Great Bay Cell and Gene Therapy Forum in Guangzhou in September 2026. The presentation covers the proposed mechanism of action, shifts in neuroinflammatory and protein biomarkers measured in cerebrospinal fluid, and clinical experience in Alzheimer's disease, with Parkinson's disease and frontotemporal dementia named as potential further indications. The approach positions immune cell therapy — long associated with oncology — as a candidate intervention in neurodegeneration.
Key Points
- Autologous NK cell therapy applied to Alzheimer's disease
- Cerebrospinal fluid biomarkers track neuroinflammatory and protein changes
- Parkinson's and frontotemporal dementia identified as further targets
Longevity Analysis
Neurodegeneration is increasingly understood as an immune-mediated process, and directing expanded natural killer cells at the inflammatory environment of the brain tests that premise directly. Measuring neuroinflammatory and protein markers in cerebrospinal fluid rather than relying on symptom scales alone gives clinicians a closer reading of what the immune compartment is actually doing inside the central nervous system — a meaningful shift for a field where late-stage interventions have repeatedly underperformed. Preserving cognitive function over decades depends on interpreting these upstream inflammatory signals long before clinical decline becomes measurable.
Original published by Longevity.Technology.